The olmesartan/rosuvastatin fixed-dose combination resulted in high medication adherence that was similar to the usual regimen of separate ARBs and statins (98.9% vs 98.3%, p=0.328).
RCT (n=150)
Open-label
1:1
No
Does olmesartan/rosuvastatin fixed-dose combination improve adherence compared to separate ARB and statin regimens in patients with high cardiovascular risk?
A fixed-dose combination of olmesartan and rosuvastatin did not significantly improve adherence compared to separate pills but resulted in a greater reduction in LDL-C.
Absolute Event Rate: 98.9% vs 98.3%
p-value: p=0.328
BACKGROUND: The efficacy of fixed-dose combinations (FDCs) in improving adherence and risk factor control for cardiovascular disease has not been reported consistently. Here, we compared adherence and efficacy between an olmesartan/rosuvastatin FDC and the usual regimen. METHODS: In this 6-month, open-label, randomized, active-control study, we screened 154 patients; of these, 150 were randomly assigned to receive either olmesartan/rosuvastatin FDC or the usual regimen with separate angiotensin receptor blockers and statins. In total, 135 patients completed the study (median age: 68 years; male: 68.9%). The primary outcome was patients' adherence; the secondary outcomes were changes in blood pressure (BP) and lipid parameters. RESULTS: During follow-up, adherence in both groups was high and similar between the groups (98.9% and 98.3% in the FDC and usual regimen groups, respectively, p = 0.328). Changes in systolic (-8 and -5 mmHg, respectively, p = 0.084) and diastolic BP (-5 and -2 mmHg, p = 0.092) did not differ significantly, although they were numerically greater in the FDC group. Changes in low-density lipoprotein cholesterol (LDL-C) were greater in the FDC group (-13 and -4 mg/dL, respectively, p = 0.019), whereas changes in other lipid parameters were similar between the groups. The test drugs were well tolerated, showing no difference in safety between the groups. CONCLUSIONS: Patients' adherence was excellent and similar in the groups, whereas the reduction in the LDL-C level was greater in the FDC group. We provide comprehensive information on the adherence and efficacy of an FDC compared to the usual regimen in Korean patients with high cardiovascular risk.
Chung et al. (Mon,) conducted a rct in Hypertension and hypercholesterolemia (n=150). Olmesartan/rosuvastatin fixed-dose combination vs. Usual regimen with separate ARBs and statins was evaluated on Adherence (p=0.328). The olmesartan/rosuvastatin fixed-dose combination resulted in high medication adherence that was similar to the usual regimen of separate ARBs and statins (98.9% vs 98.3%, p=0.328).